David Krempa Sells 19,679 Shares of Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 19,679 shares of Eton Pharmaceuticals stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total value of $619,298.13. Following the sale, the insider directly owned 25,249 shares of the company’s stock, valued at approximately $794,586.03. This trade represents a 43.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $33.39, for a total value of $1,428,991.83.
• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total value of $1,181,630.76.

Eton Pharmaceuticals Price Performance

ETON stock traded up $1.11 during mid-day trading on Wednesday, hitting $32.40. 442,334 shares of the stock were exchanged, compared to its average volume of 358,595. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The business has a fifty day moving average price of $26.33 and a 200 day moving average price of $19.94. Eton Pharmaceuticals, Inc. has a 12 month low of $13.09 and a 12 month high of $35.66. The stock has a market capitalization of $887.50 million, a price-to-earnings ratio of -462.79 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The firm had revenue of $24.27 million for the quarter, compared to the consensus estimate of $22.31 million. On average, sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cannell Capital LLC lifted its stake in shares of Eton Pharmaceuticals by 17.3% in the 3rd quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock valued at $9,896,000 after acquiring an additional 67,230 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Eton Pharmaceuticals by 44.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 351,417 shares of the company’s stock valued at $7,636,000 after acquiring an additional 108,837 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $1,922,000. Lumbard & Kellner LLC bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $3,831,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $767,000. Institutional investors own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

ETON has been the subject of several research analyst reports. Craig Hallum lifted their price target on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. HC Wainwright lifted their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Zacks Research lowered Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $41.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.